An activating point mutation in Janus kinase 2 (JAK2 V617F) was recently identified in myelofibrosis with myeloid metaplasia (MMM). To further elucidate the pathogenic significance, we examined the JAK2 mutation burden, phosphorylation of JAK2 substrates and neutrophil apoptotic resistance. Immunoblotting revealed phosphorylation of signal transducer and activator of transcription-3 (STAT3) in all four JAK2 with high V617F mutant allele burden and seven of eight with intermediate mutant allele burden, but only one of eight with wild-type JAK2 (Po0.001). In contrast, STAT5 phosphorylation was undetectable in patient MMM neutrophils; and phosphorylation of Akt and extracellular signal-regulated kinases (ERKs) failed to correlate with JAK2 mutation status. Apoptosis was lower in MMM neutrophils (median 41% apoptotic cells, n ¼ 50) compared to controls (median 66%, n ¼ 9) or other myeloproliferative disorder patients (median 53%, n ¼ 11; P ¼ 0.002). Apoptotic resistance in MMM correlated with anemia (P ¼ 0.01) and the JAK2-V617F (P ¼ 0.01). Indeed, apoptotic resistance was greatest in MMM neutrophils with high mutant allele burden (median 22% apoptosis, n ¼ 5) than with intermediate burden (median 39%, n ¼ 23) or wild-type JAK2 (median 47%, n ¼ 22; P ¼ 0.008). These results suggest that mutant JAK2 contributes to MMM pathogenesis by constitutively phosphorylating STAT3 and diminishing myeloid cell apoptosis.
Introduction
Myelofibrosis with myeloid metaplasia (MMM) is a chronic myeloproliferative syndrome that includes the entities of idiopathic myelofibrosis (or agnogenic myeloid metaplasia) as well as advanced phases of essential thrombocythemia (ET) and polycythemia vera (PV), that is, post thrombocythemic and polycythemic myeloid metaplasia, respectively. 1 Clinically, MMM is characterized by anemia, extramedullary hematopoiesis that often involves the spleen and liver, constitutional symptoms and premature death from either leukemic transformation or other disease complications. 2 Previous studies established that MMM is a stem cell-derived clonal disorder that is accompanied by intense bone marrow stromal reaction that includes collagen fibrosis, osteosclerosis and angiogenesis. 3 Although the pathogenesis of the group of disorders known as MMM had previously been unclear, it was recently reported that up to 50% of MMM samples contain a somatic mutation that results in constitutive activation of Janus kinase 2 (JAK2), [4] [5] [6] a kinase that is ordinarily activated when various cytokines such as erythropoietin, thrombopoietin, granulocyte/macrophage colony-stimulating factor (GM-CSF) and granulocyte colonystimulating factor (G-CSF) bind to their respective receptors. 7, 8 The present studies were performed to assess the potential biochemical consequences of this mutation in myeloid cells from MMM patients.
Apoptosis is an orderly series of biochemical events that result in cell shrinkage, nuclear fragmentation, packaging of cellular contents into membrane-enclosed vesicles and ultimately cell death. 9, 10 This process accounts for the rapid turnover of normal granulocytes in the circulation. 11 Under physiological conditions, important regulatory cytokines such as erythropoietin, stem cell factor (SCF) and GM-CSF function, at least in part, by inhibiting apoptosis that would otherwise occur in normal marrow progenitor cells. 12 According to current understanding, many of these cytokines regulate apoptosis through a series of steps that sequentially involve activation of receptor-associated JAK kinases, phosphorylation of cytoplasmic signal transducer and activator of transcription (STAT) proteins on specific tyrosine residues, dimerization and nuclear translocation of the phosphorylated STAT molecules and transactivation of genes that encode antiapoptotic polypeptides such as Bcl-2, Bcl-x L and Mcl-1. 7, 13, 14 For example, GM-CSF-induced activation of signaling through STAT3 has been implicated in Mcl-1 upregulation and delayed apoptosis in normal human neutrophils. 15 In chronic myelogenous leukemia (CML), Bcr-abl fusion proteins not only enhance proliferation, but also decrease apoptosis as a consequence of STAT5-mediated increase in expression of the antiapoptotic Bcl-2 family members Bcl-x L and Mcl-1. 16, 17 Because of biological similarities between CML and the other chronic myeloproliferative disorders (CMPDs), it had been suspected that the pathogenesis of these disorders might be somewhat similar. Elevated expression of Bcl-x L had been described not only in CML, but also in PV. 18 Moreover, like myeloid progenitors from CML and PV, progenitors from MMM patients exhibit the ability to grow in the absence of usually essential growth factors. 19 The biological bases for these findings were unclear until a series of recent reports described the presence of an activating V617F somatic mutation in the cytoplasmic domain of JAK2 in 35, 74 and 32% of MMM, PV and ET patients, respectively. 4, 5 Although this mutation was shown to be associated with constitutive STAT5 phosphorylation in HEL human leukemia cells, 5 it has remained unclear whether STAT5 is the pertinent transcription factor-activated downstream of JAK2 V617F in clinical MMM samples and whether this mutation alters the apoptotic threshold in this disorder.
In the present study, we have examined the relationship between JAK2 V617F mutations, STAT phosphorylation and sensitivity to apoptosis in clinical samples of MMM. We now report for the first time that JAK2 V617F mutation is associated with constitutive STAT3 phosphorylation in MMM neutrophils but not STAT5 phosphorylation. Despite the fact that Bcl-x L is not elevated in MMM neutrophils, we demonstrate a strong correlation between JAK2 V617F mutant allele burden and resistance of MMM neutrophils to apoptosis.
Materials and methods

Materials
Allophycocyanin (APC)-conjugated annexin V and recombinant human tumor necrosis factor-a (TNF-a) were obtained from BD Pharmingen (San Diego, CA, USA) and R&D Systems (Minneapolis, MN, USA), respectively. Reagents that recognize the following antigens were purchased as indicated: polyclonal antisera against phospho- 
MMM samples
After informed consent was obtained under the aegis of a protocol approved by the Mayo Clinic Institutional Review Board, peripheral blood samples were drawn from patients with clinically and histologically confirmed MMM. Mononuclear cells and neutrophils were isolated on Ficoll-Hypaque (Sigma Chemicals, St Louis, MO, USA) dual step gradients as described previously. 20, 21 All subsequent steps were performed at 41C to minimize apoptosis during processing of the samples. CD34 þ cells were isolated from the mononuclear cell fraction by reaction with anti-CD34-coupled magnetic beads followed by magnetic separation as described previously. 22 Cells were washed and lysed in buffered 6 M guanidine hydrochloride under reducing conditions 23 in preparation for sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as described below.
Neutrophils were further enriched by washing in Iscove's modified Dulbecco's medium (IMDM) and incubation in 50 mM ammonium chloride for 5 min to lyse erythrocytes. Aliquots from each specimen were stained and examined with light microscopy to confirm a uniform population of mature granulocytes (see Figure 2a) . After aliquots were removed for SDS-PAGE (see below), the remaining cells were assayed for apoptosis.
Detection of apoptosis
Neutrophils were cultured for 24 h at 371C (5% CO 2 atmosphere) in IMDM with either 20% (vol:vol) heat-inactivated fetal calf serum (to assess spontaneous apoptosis) or no serum (growth factor withdrawal-induced apoptosis). In addition, apoptosis was simulated by neutrophil incubation for 4 h with 40 ng/ml TNF-a and 0.5 mM cycloheximide as described previously. 24 The induction of apoptosis was then assessed using two assays. First, cells were subjected to three-color flow cytometry using FITC-coupled anti-CD45 (to confirm leukocyte presence), APC-coupled annexin V (detects externalization of phosphatidylserine during apoptosis 25 ) and propidium iodide (PI, a marker of cells that have lost membrane integrity). Data in the figures represent the percentage of CD45-positive cells that were negative for annexin V and PI staining. To confirm the occurrence of apoptosis, aliquots from each specimen were sedimented and stained with Wright-Giemsa stain, and examined by light microscopy for apoptotic morphologic features (see Figure 2a) .
Immunoblotting
Neutrophils were sedimented at 200 g for 10 min, washed once with ice-cold RPMI 1640 medium containing 10 mM HEPES (N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid; pH 7.4 at 41C), and lysed in ice-cold 10% (wt:vol) trichloroacetic acid to rapidly inactivate proteases as described previously. 26 Trichloroacetic acid precipitates were washed with ice-cold acetone and solubilized in buffered 6 M guanidine hydrochloride under reducing conditions. 23 Aliquots containing 50 mg protein from circulating neutrophils or CD34 þ cells (determined by the bicinchoninic acid method 27 ) were separated by SDS-PAGE on gels containing 5-15% acrylamide gradients, electrophoretically transferred to nitrocellulose and probed with immunological reagents as described. 28 
Treatment with GM-CSF
To provide an additional positive control for STAT5 phosphorylation, neutrophils from one normal control and two MMM patients were isolated as described above, incubated with 4 nM GM-CSF for 0, 5 and 15 min ex vivo, 29, 30 and prepared for electrophoresis and immunoblotting as described above.
Assessment of JAK2 mutation status
Mutation analysis for JAK2 V617F was performed in DNA derived from cytogenetic pellets in archived specimens obtained at the time of bone marrow biopsy. Genomic DNA was extracted using High Pure PCR Template Preparation Kit (Roche Diagnostics, Penzberg, Germany). Genomic DNA was amplified by PCR, and successful amplification was confirmed by electrophoresis on an ethidium bromide-impregnated 1% agarose gel. Subjects were then stratified into the following categories based on the sequencing chromatogram into (1) no mutated allele burden (only wild-type allele), (2) intermediate mutated allele burden (both wild type and mutant clearly visible) and (3) high mutated allele burden (only mutated allele visible). Samples from patients who demonstrated wild-type allele burden were then subjected to allele-specific PCR analysis validated in our laboratory. 31 In this assay, a mutation-specific forward primer is used in a PCR reaction with a wild-type sequence reverse primer containing a fluorescent tag. Only mutated DNA will be amplified, if present, and the PCR reaction product is analyzed using capillary electrophoresis with fluorescence detection. If the JAK2 V617F mutation is present, a PCR fragment of 136 basepairs is identified. Fragment analysis was performed in an ABI3100 with data collection software 1.1, GenoMapper 3.0 following the manufacturer's instructions.
Statistical analysis
The degree of apoptotic resistance (as defined by the percentage of neutrophils negative for PI and annexin V by flow cytometry) was correlated with the presence of the JAK2 V617F mutation, peripheral blood values (i.e., hemoglobin, leukocyte count, Dupriez Score, 32 
Results
Acquired JAK2 V617F mutation in MMM neutrophils is associated with STAT3 phosphorylation
In view of the known ability of active JAK2 to signal through STAT3 and STAT5, 7 we examined the phosphorylation status of these two transcription factors in whole-cell lysates prepared from circulating CD34 þ myeloid progenitors and neutrophils of MMM patients with known JAK2 mutation status. MMM patients providing samples for these and subsequent studies had complete count abnormalities, leukoerythroblastosis and frequent organomegaly that are typical for the disorder ( Table 1) . As indicated in Figure 1a , all but one of the samples of CD34 þ cells exhibited STAT3 phosphorylation regardless of their JAK2 mutation burden, possibly reflecting ongoing cytokine-mediated signaling in these cells at the time of harvest. In contrast, STAT3 phosphorylation in neutrophil samples varied with JAK2 V617F mutation burden (Figure 1a and b) . In particular, STAT3 phosphorylation was readily detectable in neutrophils expressing the JAK2 V617F allele but was extremely low or undetectable in most neutrophils lacking this mutant kinase (Figure 1a and b) . Analysis of 20 samples of MMM neutrophils revealed that STAT3 phosphorylation was readily detectable in 11 of 12 samples containing JAK2 V617F, including in four of four samples that were homozygous and seven of eight that were heterozygous, but only one of eight samples lacking the mutation (Po0.001 by Fisher's exact test). Surprisingly, STAT5 phosphorylation was not detectable in either the CD34 þ MMM progenitors or any of the 20 samples of MMM neutrophils (Figure 1a and data not shown). In contrast, leukemia cell lines contained on the blots exhibited a readily detectable signal for phospho-Tyr 694 -STAT5. Moreover, STAT5 phosphorylation was readily detected in normal or MMM neutrophils treated with GM-CSF ex vivo 29 (Figure 1c ), confirming the ability of reagents to detect this modification when present.
Previous studies have demonstrated that acute exposure to various cytokines also activates signaling through the mitogenactived protein (MAP) kinase and Akt pathways. [33] [34] [35] To determine whether activation of these pathways is also observed in neutrophils with mutant JAK2, blots of MMM neutrophils were probed with antibody to phosphorylated ERK and phosphorylated Akt as well as the non-phosphorylated polypeptides. As indicated in Figure 1b , there was no obvious pattern of Akt or ERK phosphorylation in normal versus MMM neutrophils.
Because genes encoding a number of apoptotic regulators are known to be transactivated by STAT3, 13, 14 we blotted the same samples for a series of antiapoptotic Bcl-2 family members. Consistent with previous reports that examined expression of Bcl-2 family members in normal neutrophils, 36 we observed expression of Mcl-1 and Bcl-x L but not Bcl-2 in MMM and normal neutrophils (Figure 1b) . Nonetheless, there was no obvious relationship between JAK2 mutant allele burden or STAT3 phosphorylation and levels of these polypeptides at the time of neutrophil harvest. In view of a previous report that altered regulation of the caspase inhibitor XIAP contributes to chronic neutrophilic leukemia, 26 we also blotted the MMM samples with anti-XIAP antiserum but did not observe any relationship between JAK2 mutation status and level of this polypeptide in freshly harvested neutrophils (Figure 1b) .
Neutrophils from MMM patients display resistance to apoptosis
To further evaluate potential functional consequences of the JAK2 V617F mutation, neutrophils isolated from 50 patients with MMM, 11 patients with other CMPDs and nine normal individuals were examined for ability to survive during a 24-h incubation in vitro. In these studies, neutrophil viability was defined as negative staining for both annexin V and PI as assessed by flow cytometry (Figure 2b , lower dot plots). Examination of samples from a subset of patients by light microscopy not only confirmed the presence of a relatively uniform population of mature neutrophils in each isolate, thereby excluding shift to an immature population as a potential explanation for resistance to the apoptosis described below, but also provided morphological evidence of apoptotic changes after incubation (Figure 2a) .
Comparison of neutrophils from these groups (Figure 3a ) revealed that the viability of neutrophils immediately after isolation was similar for MMM patients (median viability 92%, range 44-99%) and normal controls (median 94%, range 67-99). After a 24-h incubation in tissue culture medium in vitro, however, neutrophils from normal controls were much less viable (median viability 34%, range 0.2-46) than neutrophils from MMM patients (median 53%, range 0.2-90, P ¼ 0.002) as indicated in Figure 3b . The presence of a population of cells that were annexin V þ but PI À (upper left quadrant of lower dot plots Contribution of mutant JAK2 to MMM RA Mesa et al in Figure 2b ), along with the characteristic morphological changes (Figure 2a) , identified apoptosis as a source of this lost of viability, consistent with previous reports.
11 ,26 In order to confirm that the apoptotic resistance observed was not limited to spontaneous apoptosis, we performed several parallel experiments in which apoptosis was deliberately stimulated by serum withdrawal or treatment with TNF-a and cycloheximide. MMM neutrophils exhibited resistance to induction of apoptosis by both of these stimuli as well (Figure 3b and data not shown). Specifically, serum withdrawal induced more cell death in cell from normal neutrophils (median viability 4%, range 0.1-24) than MMM neutrophils (median viability 15%, range 0.5-96, P ¼ 0.04). Neutrophils treated with TNF-a and cycloheximide for 4 h showed a similar pattern, with a median of 37% viable cells (range 14-66, n ¼ 8 patients) in MMM samples compared with 17% (range 10-25) in normal neutrophils (n ¼ 6, P ¼ 0.03).
Apoptotic resistance in MMM neutrophils correlates with JAK2 acquired mutation burden
Of the 50 MMM samples assayed for spontaneous apoptosis after 24 h in culture with serum-containing medium, 23 (46%) had an intermediate and five (10%) had a high JAK2 V617F mutation allele burden, respectively. In univariate analysis, complete peripheral blood values, blood chemistries, physical examination findings and JAK2 mutation burden were examined for possible correlation with the degree of apoptotic resistance observed. The presence of mutant JAK2 V617F (P ¼ 0.008) and the presence of palpable splenomegaly (P ¼ 0.01) correlated with decreased apoptosis (Table 2 ). Further analysis (Figure 4a ) demonstrated that resistance to apoptosis during a 24-h culture in serum-containing medium was more pronounced in neutrophils with high JAK2 V617F mutant allele burden (median viability 78%, range 67-90) than in those with intermediate mutant allele burden (median 61% viable, range 15-93) or MMM neutrophils lacking the JAK2 V617F mutation (median 53% viable, range 16-86; P ¼ 0.008). Additional analysis demonstrated that JAK2 mutations status correlated with the presence of anemia in patients, but was not a surrogate for leukocytosis or increased myeloid immaturity in the peripheral blood (Table 2) .
Allele-specific PCR was performed on archived DNA extracted from the cytogenetic blocks of the 22/50 MMM samples that were wild type by sequencing. This highly sensitive but non-quantitative assay identified 11 additional samples that 3) and MMM patients (lanes 4-9) were subjected to SDS-PAGE followed by immunoblotting with the indicated reagents. Numbers at left, molecular weights (in kDa) of standard proteins.
were positive for the JAK2 V617F mutation. When samples that are positive for the mutant allele only by allele-specific PCR but not sequencing are combined with the samples that are positive by sequencing (Figure 4b) , the difference between samples containing any detectable JAK2 V617F (39% apoptosis) versus those that are negative in the PCR assay (46% apoptosis) is no longer significant (P ¼ 0.31). This is perhaps not surprising in view of the fact that the analysis in Figure 4a indicates a relationship between mutant allele burden and apoptotic resistance, whereas the PCR assay results in classifying samples with extremely low, intermediate and high mutant allele burden similarly (Figure 4b ).
Discussion
Previous reports established that an activating mutation in the gene encoding JAK2 is present in 35-50% of MMM samples. [4] [5] [6] The results of the present study extend this observation by demonstrating that MMM neutrophils contain phosphorylated STAT3, a known substrate of JAK2, 29 and exhibit diminished apoptosis. These observations have potentially important implications for understanding of the pathogenesis and treatment of MMM.
Neutrophils ordinarily survive for only a few hours before they spontaneously undergo apoptosis. 11, 36 A number of inflammatory cytokines, including cytokines such G-CSF and GM-CSF that can signal through JAK/STAT pathways, can prolong neutrophil survival.
7,15,36 These previous observations provide precedent for the possibility that constitutive activation of these pathways could lead to enhanced neutrophil survival. Because CML, the best understood of the CMPDs, shares phenotypic features with MMM, including splenomegaly, leukocytosis and ability of myeloid progenitors to grow ex vivo in the absence of cytokines required by normal progenitors, 19, 37, 38 it has been speculated that the pathogenesis of CML and MMM might be similar. In CML, the Bcr/abl fusion protein appears to lead to leukocyte accumulation not only through increased cell proliferation, but also through diminished apoptosis. 39, 40 This dysregulated apoptosis has been linked to Bcr/abl-mediated STAT5 activation [41] [42] [43] and the resulting STAT-mediated transactivation of genes encoding Bcl-x L and Mcl-1.
16,17
The HEL cell line, which contains the JAK2 V617F mutation, also exhibits STAT5 phosphorylation. 5 Accordingly, we expected to observe STAT5 phosphorylation in MMM leukocytes. As is shown in Figure 1 , however, STAT5 was not detectably tyrosine phosphorylated in MMM myeloid progenitors and neutrophils even though this molecule could be phosphorylated in response to exogenous GM-CSF. This observation prompted us to examine STAT3, another substrate of JAK2 in neutrophils. 29 Interestingly, tyrosine phosphorylation of STAT3 was readily detected in MMM neutrophils bearing the JAK2 V617F mutation (Figure 1 ). Although the factors that contribute to differential phosphorylation of STAT3 versus STAT5 remain to be elucidated, it is important to note that differential activation of STAT3 has also been observed in some samples of acute myelogenous leukemia, 13 multiple myeloma 47 and a variety of solid tumors. 13, 14, 48 The present observations extend these findings for the first time to MMM.
To evaluate the possibility that additional prosurvival pathways were also activated in MMM neutrophils bearing the JAK V617F mutation, we also examined phosphorylation of Akt and ERK in MMM and normal neutrophils. Even though the MAP kinase and phosphatidylinositol-3 kinase/Akt pathways are both activated by cytokine treatment, 33 these pathways were not differentially activated in MMM neutrophils with the JAK2 V617F mutation compared to other neutrophil samples (Figure 1b) . It is important to emphasize, however, that samples were harvested for immunoblotting immediately after isolation (to minimize loss of the most susceptible cells by spontaneous apoptosis) and were not deprived of cytokines for prolonged periods to downregulate basal signaling as is often the case in studies of tissue culture cell lines. Thus, further studies in tissue culture cells are required to rule out the possibility that JAK2 V617F-associated differences in signaling through the MAP kinase and Akt pathways have been obscured by the use of fresh specimens in the present study. Alternatively, it is possible that mutant JAK2 preferentially activates one of its downstream targets (STAT3) in much the same way that mutant epidermal growth factor receptor has recently been shown to preferentially activate signaling through one of its downstream pathways. 49 Because STAT3 and STAT5 transactivate genes encoding a number of antiapoptotic Bcl-2 family members, 13, 14 we next examined expression of Bcl-2, Bcl-x L and/or Mcl-1 in MMM neutrophils harboring the JAK2 V617F mutation. To our disappointment, levels of the antiapoptotic Bcl-2 family members assayed (Figure 1b) as well as the proapoptotic Bcl-2 family members Bax, Bak, Bim and Bmf (data not shown) in MMM and normal neutrophils were indistinguishable. Although this observation might reflect the fact that polypeptide levels were examined in whole-cell lysates from freshly isolated neutrophils rather than neutrophils subjected to proapoptotic stress, 26 it is important to emphasize that other signal-transduction pathways also regulate the expression and activation of these genes. 50, 51 Conversely, we were unable to detect A1, another STAT3-regulated antiapoptotic Bcl-2 family member, 33 by immunoblotting (DL and SHK, data not shown). Moreover, it is possible that one or more STAT3-activated genes other than Bcl-2 family members play a role in the pathogenesis of MMM. At the present time, the STAT3 transcriptional response is only partially understood, with a large number of STAT3 transcriptional targets being identified just in the last few months. 52, 53 Further study of these STAT3 targets in the context of differentiating myeloid progenitors might be required before the full implication of STAT3 phosphorylation in MMM progenitors is completely appreciated.
To determine whether the JAK2 V617F mutation and consequent STAT3 phosphorylation have phenotypic consequences, we examined spontaneous and induced apoptosis in MMM neutrophils. Compared to neutrophils from normal individuals, MMM neutrophils exhibited diminished spontaneous apoptosis (Figures 2 and 3) as well as diminished apoptosis in response to withdrawal of serum-survival factors (Figure 3b ) or treatment with TNF-a and cycloheximide (not shown). These observations rule out the possibility that MMM neutrophils are simply resistant to a single proapoptotic stimulus. Interestingly, the degree of resistance in MMM neutrophils correlated with the JAK2 V617F mutant allele burden (Figure 4a ). The present observation that cells with homogeneous JAK2 V617F are more resistant to the induction of apoptosis under unfavorable survival conditions (Figure 4a ) provides a mechanism that potentially contributes to progressive emergence of clones with homogeneous JAK2 V617F mutations (high mutant allele burden) in some patients with CMPDs. Not surprisingly, this relationship between mutant allele burden and apoptotic resistance was obscured when samples that were negative by sequencing and only had very low-level mutant allele burden by PCR were combined with samples that had intermediate or high mutant allele burden by PCR (Figure 4b ). These observations illustrate the importance of grouping samples by similar JAK2 V617F mutation burden rather than simply classifying them as positive or negative for JAK2 V617 mutation in future studies of MMM cell biology.
The present results not only provide potential insight into the pathogenesis of MMM, but also raise the possibility of new treatments. 55 A variety of STAT3-directed therapeutic approaches are currently undergoing preclinical investigation. 13, 48, 55, 56 Although the observation that JAK2 mutations are frequent in MMM [4] [5] [6] suggests that JAK2 inhibitors might have potential efficacy in a subset of patients with this disease, the present observations raise the possibility that STAT3-directed therapies might also have a role. Further investigation to determine whether these STAT3-directed approaches might be useful, either alone or in combination with JAK2 inhibitors to diminish the emergence of resistance to the latter agents, appears warranted. Samples that were negative for JAK V617F by sequencing were subjected to allele-specific PCR. 31 Samples that were negative in the PCR assay (n ¼ 11) were then compared to samples that were positive by allele-specific PCR or sequencing (n ¼ 39) without distinction among different levels of mutant allele burden. Each point represents one clinical sample. Horizontal bars, median values for each group. Error bars, 71 s.d.
